



Urgent Field Safety Notice

CC 17-10.A.OUS

April 2017

ADVIA Centaur®
ADVIA Centaur® XP
ADVIA Centaur® XPT
ADVIA Centaur® CP

ADVIA Centaur Systems Insulin Assay: Standardization to WHO 1st IRP 66/304

Our records indicate that your facility may have received the following product:

Table 1. ADVIA Centaur Affected Product(s)

Assay	Test Code	Catalog Number	Siemens Material Number (SMN)	Kit Lots ending	Expiration Date	Date of Manufacture
ADVIA Centaur Systems Insulin Calibrator	Calibrator IRI	04618899	10310438	59	2017-Apr-05	2015-Sep-17
				67	2017-Aug-22	2016-Mar-15
				70	2017-Nov-27	2016-Jun-09
				74	2017-Feb-26	2016-Aug-17
ADVIA Centaur Systems Insulin ReadyPack	IRI	02230141	10310439	169	2017-Apr-11	2016-Apr-11
				170	2017-May-27	2016-May-27
				173	2017-Jun-30	2016-Jun-30
				174	2017-Aug-26	2016-Aug-26

Reason for Correction

Siemens Healthcare Diagnostics is providing this Urgent Field Safety Notice to communicate the restoration of the ADVIA Centaur Systems Insulin (IRI) assay to World Health Organization (WHO) 1st IRP 66/304 standardization.

Siemens internal investigation has identified that current in-date lots of ADVIA Centaur Systems Insulin recover approximately 40% higher than the World Health Organization (WHO) 1st IRP 66/304 standardization based on slope values. The slope value was observed to be 1.40 on the ADVIA Centaur XP and 1.42 on the ADVIA Centaur CP.

Siemens has confirmed that the assay's reportable range, reference interval, precision, analytical sensitivity, hook effect and linearity are not impacted by this issue and continue to meet the assay performance characteristics stated in the assay Instructions for Use (IFU). Investigation also concluded that root cause of this issue is related to a raw material used during the manufacture of the IRI calibrators.

This issue has been corrected and standardization to WHO 1st IRP 66/304 has been restored beginning with ADVIA Centaur IRI ReadyPack kit lots ending in 201 when paired with IRI Calibrator kit lots ending in 02, which will be available by May 2017. For observed biases at specific clinical intervals that customers may observe after the correction is implemented, refer to Table 4 and Table 5 in this letter.

Risk to Health

With current in-date reagent lots, the potential exists for misinterpretation of insulin levels when comparing to standardization to the World Health Organization (WHO) 1st IRP 66/304. The reference interval for insulin is not impacted as a result of this issue. Insulin testing is not generally used in isolation in clinical practice. Additional laboratory testing is typically performed along with insulin, such as glucose, HbA1c, c-peptide, and proinsulin. Potential clinical impact is also mitigated by correlation to clinical history and symptomology. Siemens is not recommending a review of previously generated results.

Actions to be Taken by the Customer

- Please review this letter with your Medical Director.
- Customers may continue to use existing product to report results until the re-standardized product is available. Corrected product, beginning with ADVIA Centaur Systems Insulin ReadyPack kit lots ending in 201 and IRI Calibrator kit lots ending in 02, will be available by May 2017.
- Upon receipt of ADVIA Centaur Systems Insulin ReadyPack kit lots ending in 201 (and future lots) and IRI Calibrator kit lots ending in 02 (and future lots), discontinue use of the product listed in Table 1.
- Refer to the Bio-Rad website for revised control targets and ranges to be used with corrected product. For all other commercially available controls, evaluate the need for target reset.
- Review the Additional Information section of this letter for further details regarding expected performance.
- Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days.
- If you have received any complaints of illness or adverse events associated with the products listed in Table 1, immediately contact your local Siemens Customer Care Center or your local Siemens technical support representative.

Please retain this letter with your laboratory records, and forward this letter to those who may have received this product.

Additional Information

Table 2 provides the results of the current state method comparison, using serum samples across the assay range. Current state refers to ReadyPack kit lots ending in 174 and below and Calibrator kit lots ending in 74 and below, as listed in Table 1 of this letter.

Table 2: Current State Method Comparison: ADVIA Centaur Systems IRI vs. WHO

X-Axis	Y-Axis	N	Range of Samples (U/mL)	Slope	Intercept (U/mL)
WHO 1 st IRP 66/304 Material	ADVIA Centaur/XP/XPT	297	0.48 - 225	1.40	-1.35
WHO 1 st IRP 66/304 Material	ADVIA Centaur CP	296	0.57 - 215	1.42	-1.44

Table 3 provides the results of the re-standardized method comparison, using serum samples across the assay range. Re-standardized refers to ReadyPack kit lots ending in 201 and future lots with Calibrator kit lots ending in 02 and future lots.

Table 3: Re-Standardized Method Comparison: ADVIA Centaur Systems IRI vs. WHO

X-Axis	Y-Axis	N	Range of Samples (U/mL)	Slope	Intercept (U/mL)
WHO 1 st IRP 66/304 Material	ADVIA Centaur/XP/XPT	304	0.48 - 239	1.01	-0.05
WHO 1 st IRP 66/304 Material	ADVIA Centaur CP	302	0.57 - 215	1.01	0.08

Table 4 and Table 5 provide serum sample results obtained during Siemens internal verification testing, comparing re-standardized product to current state. Based on this data set, the average % Bias expected in the range of 0.5 mU/L to 30 mU/L is approximately -23% on the ADVIA Centaur XP system and approximately -30% on the ADVIA Centaur CP system.

Customers should expect to see a change when they begin to use the re-standardized product. Slight differences in observed results may be attributed to different demographics of patient samples used by each laboratory.

Table 4: ADVIA Centaur XP: Serum Sample Results (Re-Standardized vs. Current State)

Segment (mU/L)	N	Average Absolute Bias (mU/L)	Absolute Bias Range (mU/L)	Average % Bias	% Bias Range
0.5 - 10	33	-1.6	-0.4 to -2.3	-23.9%	-15.9% to -25.8%
>10 - 30	56	-4.1	-1.7 to -7.6	-22.7%	-15.6% to -27.3%
>30 - 50	12	-10.0	-8.6 to -11.6	-26.1%	-21.8% to -29.1%
>50 - 100	10	-13.8	-10.1 to -22.6	-20.5%	-17.4% to -24.3%
>100 - 300	15	-55.5	-28.3 to -66.9	-32.1%	-25.5% to -37.1%

Table 5: ADVIA Centaur CP: Serum Sample Results (Re-Standardized vs. Current State)

Segment (mU/L)	N	Average Absolute Bias (mU/L)	Absolute Bias Range (mU/L)	Average % Bias	% Bias Range
0.5 - 10	33	-1.6	-0.6 to -2.5	-32.4%	-27.1% to -41.1%
>10 - 30	56	-4.1	-1.8 to -8.2	-28.5%	-19.0% to -39.7%
>30 - 50	12	-10.1	-7.5 to -11.4	-35.0%	-30.1% to -39.6%
>50 - 100	10	-15.5	-9.9 to -30.8	-28.1%	-19.1% to -41.4%
>100 - 300	15	-56.8	-26.7 to -71.6	-49.5%	-33.2% to -67.3%

A negative shift in quality control values will also be observed with the ADVIA Centaur Systems IRI ReadyPack kit lots ending in 201 (and future lots) when used in conjunction with IRI calibrator kit lots ending in 02 (and future lots). Please refer to the Bio-Rad website for revised targets and ranges for Bio-Rad control products.

We apologize for the inconvenience this situation may cause. If you have any questions, please contact your Siemens Customer Care Center or your local Siemens technical support representative.

Product availability may vary from country to country and is subject to varying regulatory requirements. Due to local regulations, the ADVIA Centaur XPT is not available in all countries.

ADVIA Centaur is a trademark of Siemens Healthcare Diagnostics.